Recombinant Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)
![Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)](https://www.abcam.com/ps/products/233/ab233693/Images/ab233693-307755-anti-vegf-receptor-2-antibody-epr21884-236-flow-cytometry.jpg "Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR21884-236] to VEGF Receptor 2
- Suitable for: Indirect ELISA, Flow Cyt, ICC/IF
- Reacts with: Mouse
Related conjugates and formulations
Overview
-
Product name
Anti-VEGF Receptor 2 antibody [EPR21884-236]
See all VEGF Receptor 2 primary antibodies -
Description
Rabbit monoclonal [EPR21884-236] to VEGF Receptor 2 -
Host species
Rabbit -
Tested applications
Suitable for: Indirect ELISA, Flow Cyt, ICC/IFmore details -
Species reactivity
Reacts with: Mouse -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- ICC/IF: bEnd.3 cells. Flow Cyt: bEnd.3 cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR21884-236 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab233693 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Indirect ELISA |
Use at an assay dependent concentration.
|
|
| Flow Cyt |
1/500.
|
|
| ICC/IF |
1/1000.
|
| Notes |
|---|
|
Indirect ELISA
Use at an assay dependent concentration. |
|
Flow Cyt
1/500. |
|
ICC/IF
1/1000. |
Target
-
Function
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 16542 Mouse
- SwissProt: P35918 Mouse
- Unigene: 285 Mouse
-
Alternative names
- CD309 antibody
- CD309 antigen antibody
- EC 2.7.10.1 antibody
see all
Images
-
Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)
Flow cytometric analysis of bEnd.3 (mouse brain endothelioma cell line) cell line treated with 1 μg/ml Brefeldin A for 3 hours (red) and an untreated control (green) labeling VEGF Receptor 2 with ab233693 at 1/500 dilution treated with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.
BFA treatment reduced cell surface VEGF Receptor 2 [PMID: 21063020].
Gated on viable cells.
-
![Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)](https://www.abcam.com/ps/products/233/ab233693/Images/ab233693-307752-anti-vegf-receptor-2-antibody-epr21884-236-immunofluorescence.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized bEnd.3 (mouse brain endothelioma cell line) and NIH/3T3 (mouse embryo fibroblast cell line) cells labeling VEGF Receptor 2 with ab233693 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing perinuclear staining in bEnd.3 cells.
Negative control: NIH/3T3 [PMID: 20978347].
The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.
-
![Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)](https://www.abcam.com/ps/products/233/ab233693/Images/ab233693-307754-anti-vegf-receptor-2-antibody-epr21884-236-flow-cytometry.jpg)
Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)Flow cytometric analysis of bEnd.3 (mouse brain endothelioma cell line, right) and NIH/3T3 (mouse embryo fibroblast cell line, left) cell line labeling VEGF Receptor 2 with ab233693 at 1/500 dilution compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.
Gated on viable cells.
Negative control: NIH/3T3 [PMID: 20978347].
-
![Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)](https://www.abcam.com/ps/products/233/ab233693/Images/ab233693-307753-anti-vegf-receptor-2-antibody-epr21884-236-immunofluorescence.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized bEnd.3 (mouse brain endothelioma) cells labeling VEGF Receptor 2 with ab233693 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Redistribution of the VEGF Receptor 2 from the perinuclear Golgi to vesicular structures throughout the cytosol after treatment with Brefeldin A (1 μg/ml, 3 hours) in bEnd.3. BFA treatment alters the subcellular localisation of VEGF Receptor 2 [PMID: 21063020].
The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.
-
![Indirect ELISA - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)](https://www.abcam.com/ps/products/233/ab233693/Images/ab233693-6-anti-vegf-receptor-2-antibody-epr21884-236-elisa-mouse-vegf-r2.jpg)
Indirect ELISA - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)ELISA analysis of Mouse VEGF R2 recombinant protein at 1000 ng/mL with ab233693. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution was used as the secondary antibody.
-
![Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)](https://www.abcam.com/ps/products/233/ab233693/Images/ab233693-5-benefits-of-recombinant-antibodies.png)
Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (2)
ab233693 has been referenced in 2 publications.
- Yang L et al. MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 87:125-134 (2021). PubMed: 33141330
- Xu J et al. Therapeutic effects of CXCR4+ subpopulation of transgene-free induced cardiosphere-derived cells on experimental myocardial infarction. Cell Prolif 54:e13041 (2021). PubMed: 33942933